Malin is a publicly listed company investing in highly innovative life sciences companies.

We focus on oncology, immunology and genetic diseases where we believe innovative life science and healthcare technologies will deliver transformative treatments for patients.

Discover Our Story

Our purpose is to deliver significant returns for shareholders and transformative outcomes for patients through the application of long-term capital and strategic support to our investee companies to enable them to reach their value potential.

Malin Assets

Malin Businesses

Latest News

Investee Company News

Malin RNS Announcements

08 Apr 2024

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

13 Mar 2024

Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

07 Mar 2024

Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023

28 Feb 2024

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

More News>